Well, I would say that the previous marketcap (before the deal) was already baking in something other than continued losses, no?
regarding the derisking part, I dont quite understand it. If the company keeps its costs for the clinical trials + admin at 24M, to justify the current price (following my previous logic), the revenue coming from the clinical trials would have to be $30 million. I'm not saying it wont be even higher, but there was already one time when things didn't go according to plan,right? Can that happen again?
Putting numbers on it, page-5
-
- There are more pages in this discussion • 43 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CGS (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
90.0¢ |
Change
-0.040(4.26%) |
Mkt cap ! $155.3M | |||
| Open | High | Low | Value | Volume |
| 91.0¢ | 91.5¢ | 89.5¢ | $13.66K | 15.16K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 8443 | 90.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 94.0¢ | 4762 | 2 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| CGS (ASX) Chart |